多西他赛与BRCA-1在胃癌个体化治疗中的相关性研究

目的：探讨以多西他赛为基础的化疗药物与BRCA-1 mRNA在胃癌个体化治疗中的相关性。方法：采用实时荧光定量逆转录聚合酶链反应检测74例胃癌患者组织标本中BRCA-1 mRNA的表达水平，比较其与接受不同化疗方案患者生存情况之间的关联。结果：BRCA-1 mRNA低表达者42例（56.76%），高表达者32例（43.24%），BRCA-1 mRNA表达水平与临床病理特征无关（P＞0.05）。BRCA-1 mRNA高表达者经多西他赛辅助化疗后其中位总生存期显著长于低表达者（48.1 vs 11.1个月，P=0.009）；高表达者的无疾病生存期长于低表达患者（25.1 vs 7.1个月，P=0.038）。Cox多因素回归分析显示，BRCA-l mRNA表达水平是影响胃癌患者预后的独立因素。在使用奥沙利铂的22例患者中，BRCA-1 mRNA低表达患者中位总生存期长于高表达患者（40.8 vs 17.3个月，P=0.556）；低表达患者无疾病生存期长于高表达患者（33.1 vs 10.5个月，P=0.345）。结论：BRCA-1 mRNA表达水平可作为接受多西他赛化疗的胃癌患者预后的独立预测因素。

Study on Correlation between Docetaxel and BRCA-1 in Individualized Treatment of Gastric Cancer

Objective: To study the correlation between docetaxel-based chemotherapeutics and BRCA-1 in individualized treatment of gastric cancer. Methods: The RT-qPCR technique was used to detect the expression level of BRCA-1 mRNA in 74 patients of gastric cancer. The correlation between BRCA-1 mRNA expression and survival of patients receiving different therapeutic regimens was analyzed. Results: The number of low and high BRCA-1 mRNA expression was 42 (56.76%) and 32 (43.24%), respectively. BRCA-1 mRNA had no significant correlation with clinicopathological parameters (P>0.05). After the treatment based on docetaxel, the median overall survival (OS) of patients with the high BRCA-1 mRNA expression was longer than that of patients with the low BRCA-1 mRNA expression (48.1 vs 11.1 months, P=0.009); the median disease-free survival time (DFS) of patients with the high BRCA-1 expression was longer than that of patients with the low BRCA-1 expression expression (25.1 vs 7.1 months, P=0.038). The COX multivariate analysis results showed that the BRCA-l mRNA expression was an independent factor which could influence the prognosis of gastric cancer patients. After the treatment based on oxaliplatin, the OS of patients with the low BRCA-1 mRNA expression was longer than that of patients with the high BRCA-1 mRNA expression (40.8 vs 17.3 months, P=0.556); the median DFS of patients with the low BRCA-1 expression was longer than that of patients with the high BRCA-1 expression expression (33.1 vs 10.5 months, P=0.345). Conclusion: BRCA-1 mRNA expression can be used as an independent predictive factor for the prognosis of the gastric cancer patients receiving docetaxel.